Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co.'s development plan for STS101 included a completed Phase 1 trial; a Phase 3 efficacy trial (the SUMMIT trial), which is ongoing; and continuation of the open-label, Phase 3 long-term safety trial of STS101 (the ASCEND trial). We show 16 historical shares outstanding datapoints in our coverage of STSA's shares outstanding history.
Understanding the changing numbers of STSA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like STSA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching STSA by allowing them to research STSA shares outstanding history
as well as any other stock in our coverage universe. |
Free STSA Email Alerts:
Video: Shares Outstanding Importance
